# OnCo record ciltacabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ciltacabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ciltacabtagene-autoleucel" ;
  schema:name "Ciltacabtagene autoleucel"@en ;
  schema:description "Ciltacabtagene autoleucel is a one-time BCMA CAR-T for myeloma that, in CARTITUDE-4, cut the risk of death by about 45% compared with standard regimens."@en ;
  schema:url <https://onco.cc/drugs/ciltacabtagene-autoleucel/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ciltacabtagene_autoleucel> ;
  owl:sameAs <http://www.wikidata.org/entity/Q111948874> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ciltacabtagene%20autoleucel> ;
  onco:status "approved" ;
  onco:modality "CAR-T (BCMA)" ;
  schema:alternateName "Carvykti" ;
  onco:approval "US 2022: Relapsed/refractory myeloma ≥4 lines", "US 2024: Relapsed myeloma after ≥1 line, lenalidomide-refractory" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/legend-biotech/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/nct06550895/>, <https://onco.cc/trials/nct04133636/>, <https://onco.cc/trials/nct06577025/>, <https://onco.cc/trials/nct07149857/> .